Lauren Santye, Assistant Editor

African Americans with breast cancer have a 40% higher death rate than European-Americans.

Top news of the day from across the health care landscape.

The interchangeability designation demonstrates that the efficacy and safety of a biosimilar is equal to the reference product.

MicroRNAs could monitor the severity of MS in the future.

Common diabetes drug changes the biology of cancer cells.

Time of day is an important factor in chemotherapy-induced adverse events.

Pro-inflammatory cervicovaginal bacteria increased HIV risk more than 4-fold in women.

Top news of the day from across the health care landscape.

Smoking is a risk factor for breaking tolerance to multiple autoantigens in RA.

Findings may lead to preventative treatments for breast cancer, such as anti-inflammatory drugs.

HCV rates 3 times higher in patients with lupus.

Top news of the day from across the health care landscape.

African American women account for 62% of women diagnosed with HIV.

Top articles of the week from Specialty Pharmacy Times.

Ninety-three percent of women reported at least 1 adverse event from breast cancer treatment.

Scientists used a novel approach for imaging the movement of immune cells in mouse models of RA.

Immunotherapy also found to prolong life in patients with bladder cancer.

Targeting immune cells entering joints may prevent inflammatory arthritis.

Young and middle-aged adults with colon cancer are 2 to 8 times more likely to receive postoperative chemotherapy.

Computer algorithm for skin cancer matched performance of human dermatologists.

Younger patients with colon cancer are more likely to be administered postoperative chemotherapy.

Application pulled for biosimilar that treats neutropenia.

Congress, regulators, and the media expected to place pressure on pharmacy benefit managers in the coming months.

TNFis improve the burden of comorbidity associated with RA.

Combination treatment prior to surgery changes the clinical significance of growth factors as potential biomarkers.

Prevention programs, HIV testing, and easier access to treatment are all areas that need to be addressed.

Fake hepatitis C pills are entering the distribution network through back-channel wholesalers.

Teva loses patent infringement litigations for Copaxone.

Top news of the day from across the health care landscape.

Would federal funding cuts to the Ryan White Care Act be "devastating" to the HIV-positive population?